← Back to Search
Nimodipine Restores The Altered Hippocampal Phenytoin Pharmacokinetics In A Refractory Epileptic Model
C. Höcht, A. Lazarowski, N. González, J. Auzmendi, E. Girardi
Published 2007 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The present work was undertaken to examine the central pharmacokinetics of phenytoin (PHT) in an experimental model of epilepsy, induced by administration of 3-mercaptopropionic acid (MP), and possible participation of P-glycoprotein in this model of epilepsy. Repeated seizures were induced in male Wistar rats by injection of 3-MP (45 mg kg(-1), i.p.) during 10 days. Control rats (C) were injected with saline solution. In order to monitor extracellular PHT levels, either a shunt microdialysis probe or a concentric probe was inserted into carotid artery or hippocampus, respectively. All animals were administered with PHT (30 mg kg(-1), i.v.) 30 min after intraperitoneal administration of vehicle (V) or nimodipine (NIMO, 2 mg kg(-1)). No differences were found in PHT plasma levels comparing all experimental groups. In pre-treated rats with V, hippocampal PHT concentrations were lower in MP (maximal concentration, C(max): 2.7+/-0.3 microg ml(-1), p<0.05 versus C rats) than in C animals (C(max): 5.3+/-0.9 microg ml(-1)). Control rats pre-treated with NIMO showed similar results (C(max): 4.5+/-0.8 microg ml(-1)) than those pre-treated with V. NIMO pre-treatment of MP rats showed higher PHT concentrations (C(max): 6.8+/-1.0 microg ml(-1), p<0.05) when compared with V pre-treated MP group. Our results indicate that central pharmacokinetics of PHT is altered in MP epileptic rats. The effect of NIMO on hippocampal concentrations of PHT suggests that P-glycoprotein has a role in reduced central bioavailability of PHT in our epileptic refractory model.
This paper references
Practical aspects of using microdialysis for determination of brain interstitial concentrations
H. Benveniste (1991)
Modification of [3H]MK801 Binding to Rat Brain NMDA Receptors after the Administration of a Convulsant Drug and an Adenosine Analogue: A Quantitative Autoradiographic Study
L. Giraldez (2004)
P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice
G. Sills (2002)
CONVULSANT ACTIVITY OF HOMOCYSTEINE AND OTHER SHORT‐CHAIN MERCAPTOACIDS: PROTECTION THEREFROM *
H. Sprince (1969)
Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain
H. Potschka (2001)
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
M. Fromm (2000)
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
A. Schinkel (1996)
In Vivo Evidence for P‐Glycoprotein–Mediated Transport of Phenytoin at the Blood–Brain Barrier of Rats
H. Potschka (2001)
Comparison of Brain Extracellular Fluid, Brain Tissue, Cerebrospinal Fluid, and Serum Concentrations of Antiepileptic Drugs Measured Intraoperatively in Patients with Intractable Epilepsy
B. Rambeck (2006)
Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.
V. Höllt (1992)
Limbic Seizures Induce P-Glycoprotein in Rodent Brain: Functional Implications for Pharmacoresistance
M. Rizzi (2002)
The Rat Brain in Stereotaxic Coordinates
G. Paxinos (1983)
Primary care : epilepsy
T. Brown (2001)
P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain
H. Potschka (2001)
Microdialysis in the neurosciences
T. Robinson (1991)
Neuronal and Glial Expression of the Multidrug Resistance Gene Product in an Experimental Epilepsy Model
A. Lazarowski (2004)
Microdialysis in drug discovery.
C. Höcht (2004)
Clinical aspects and biological bases of drug-resistant epilepsies
G. Regesta (1999)
Calcium modulation in epilepsy.
W. Kułak (2004)
Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents
G. Sarro (2003)
Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.
C. Pascaud (1998)
Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats
L. Belayev (1996)
Inhibition of the Multidrug Transporter P‐Glycoprotein Improves Seizure Control in Phenytoin‐treated Chronic Epileptic Rats
E. V. van Vliet (2006)
A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats
H. Potschka (2002)
P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: evidence from microdialysis experiments in rats
H. Potschka (2002)
Drug resistance in brain diseases and the role of drug efflux transporters
W. Löscher (2005)
Cytochromes P450 and experimental models of drug metabolism
R. Zuber (2002)
Drug Transport in the Mammalian Central Nervous System: Multiple Complex Systems
R. Spector (2000)
Astrocytic Response in Hippocampus and Cerebral Cortex in an Experimental Epilepsy Model
E. Girardi (2004)
Effect of nimodipine, a dihydropyridine calcium channel antagonist on the pharmacokinetics of carbamazepine in rhesus monkeys.
M. Gupta (2003)
Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters.
C. Höcht (2003)
Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
A. Lazarowski (2006)
Molecular and cellular mechanisms of pharmacoresistance in epilepsy.
Stefan Remy (2006)
This paper is referenced by
High fructose diet increases anterior hypothalamic alpha 2-adrenoceptors responsiveness
M. Mayer (2007)
Modulating P‐glycoprotein regulation: Future perspectives for pharmacoresistant epilepsies?
H. Potschka (2010)
Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions
A. Lazarowski (2011)
Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations
R. Clinckers (2009)
High incidence of persistent subtherapeutic levels of the most common AEDs in children with epilepsy receiving polytherapy
L. Czornyj (2018)
Recovery of Motor Spontaneous Activity After Intranasal Delivery of Human Recombinant Erythropoietin in a Focal Brain Hypoxia Model Induced by CoCl2 in Rats
A. Merelli (2010)
Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources
Daniel Pérez-Pérez (2019)
Role of P‐glycoprotein inhibitors in children with drug‐resistant epilepsy
H. El-Khayat (2017)
Microdialysis as a Tool to Unravel Neurobiological Mechanisms of Seizures and Antiepileptic Drug Action
I. Smolders (2011)
Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV.
D. Chiappetta (2013)
P-glycoprotein contributes to cell membrane depolarization of hippocampus and neocortex in a model of repetitive seizures induced by pentylenetetrazole in rats.
Jerónimo A Auzmendi (2013)
P-Glycoprotein—a Clinical Target in Drug-Refractory Epilepsy?
R. Robey (2008)
Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus
E. C. Lange (2010)
Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations.
Francesca Rivers (2008)
Vigabatrin extracellular pharmacokinetics and concurrent γ‐aminobutyric acid neurotransmitter effects in rat frontal cortex and hippocampus using microdialysis
X. Tong (2009)
Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions
Jerónimo Auzmendi (2020)
Acute toxicity and anticonvulsant activity of liposomes containing nimodipine on pilocarpine-induced seizures in mice
L. C. G. A. I. Moreno (2015)
Progressive heart P-glycoprotein (P-gp) overexpression after experimental repetitive seizures (ERS) associated with fatal status epilepticus (FSE). Is it related with SUDEP?
A. Lazarowski (2014)
Phenytoin carried by silica core iron oxide nanoparticles reduces the expression of pharmacoresistant seizures in rats.
Argelia Rosillo-de la Torre (2015)
Pharmacoresistant epilepsy and nanotechnology.
Argelia Rosillo-de la Torre (2014)
Influence of the dual combination of silymarin and (-)-epigallocatechin gallate, natural dietary flavonoids, on the pharmacokinetics of oxcarbazepine in rats.
A. Ferreira (2017)
Role of Oxidative Stress in Refractory Epilepsy: Evidence in Patients and Experimental Models
N. Cárdenas-Rodríguez (2013)
Methods and Applications of Epilepsy Assays
M. Zhao (2009)
Role of ABC-Transporters in Epileptogenesis and Pharmacoresistant Epilepsy
Lazarowski Alberto (2016)
ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches.
Kevin Leandro (2019)
Pharmacoresistance in Epilepsy
L. Rocha (2013)
Trimetazidine exerts protection against increasing current electroshock seizure test in mice
S. Jain (2010)
Molecular Mechanisms of Pharmacoresistant Epilepsy
A. Lazarowski (2013)
Cerebral expression of drug transporters in epilepsy.
E. Aronica (2012)
(R)-[11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus
S. Syvänen (2011)
New model of pharmacoresistant seizures induced by 3-mercaptopropionic acid in mice
Andrea V. Enrique (2017)
Erythropoietin as Potential Neuroprotective and Antiepileptogenic Agent in Epilepsy and Refractory Epilepsy
Amalia Marelli (2016)See more